PAR-22-208: Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 7, 2022.
From the official notice on Grants.gov, last changed June 27, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$1.4 million
- Typical project length8 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under PAR-22-208 were run by National Institute of Neurological Disorders and Stroke (NINDS, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-208 in the NIH Guide.
Key dates
| Posted | June 27, 2022 |
|---|---|
| Deadline | October 7, 2022 |
| Archived by Grants.gov | November 12, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.
Funded under PAR-22-208 so far
NIH funded 6 projects under PAR-22-208 in fiscal 2023 to 2026, at 3 institutions. The median yearly award was $1.4 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Structure of amyloid fibrils in human neurodegenerative diseases and aging | Indiana University Indianapolis | 2026 | $154,275 |
| Structural characterization of tau aggregation variability and maturity in isolated cell types of the brain | University of California, San Francisco | 2026 | $818,240 |
| Structural Biology of Alpha-Synuclein in Lewy Body Dementia | Washington University | 2026 | $1.4 million |
| Structural Biology of Alpha-Synuclein in Lewy Body Dementia | Washington University | 2023 | $4.2 million |
| Structural characterization of tau aggregation variability and maturity in isolated cell types of the brain | University of California, San Francisco | 2023 | $2.4 million |
| Structure of amyloid fibrils in human neurodegenerative diseases and aging | Indiana University Indianapolis | 2023 | $3.9 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-208 still open?
No. It closed on October 7, 2022.
Who can apply for Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed)?
Closed October 7, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-208?
NIH RePORTER lists 6 projects funded under PAR-22-208 in fiscal 2023 to 2026, at 3 institutions. The most were at Indiana University Indianapolis, University of California, San Francisco, Washington University.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)